A PCA approach to population analysis: with application to a Phase II depression trial

For psychiatric diseases, established mechanistic models are lacking and alternative empirical mathematical structures are usually explored by a trial-and-error procedure. To address this problem, one of the most promising approaches is an automated model-free technique that extracts the model structure directly from the statistical properties of the data. In this paper, a linear-in-parameter modelling approach is developed based on principal component analysis (PCA). The model complexity, i.e. the number of components entering the PCA-based model, is selected by either cross-validation or Mallows’ Cp criterion. This new approach has been validated on both simulated and clinical data taken from a Phase II depression trial. Simulated datasets are generated through three parametric models: Weibull, Inverse Bateman and Weibull-and-Linear. In particular, concerning simulated datasets, it is found that the PCA approach compares very favourably with some of the popular parametric models used for analyzing data collected during psychiatric trials. Furthermore, the proposed method performs well on the experimental data. This approach can be useful whenever a mechanistic modelling procedure cannot be pursued. Moreover, it could support subsequent semi-mechanistic model building.

[1]  Thierry d'Amato,et al.  Validity of the depressive dimension extracted from principal component analysis of the PANSS in drug-free patients with schizophrenia , 2002, Schizophrenia Research.

[2]  Donald A. Jackson,et al.  How many principal components? stopping rules for determining the number of non-trivial axes revisited , 2005, Comput. Stat. Data Anal..

[3]  W. Berry LARGE SCALE SPARSE SINGULAR VALUE COMPUTATIONSMICHAEL , 1992 .

[4]  An Vermeulen,et al.  Structural Models Describing Placebo Treatment Effects in Schizophrenia and Other Neuropsychiatric Disorders , 2011, Clinical pharmacokinetics.

[5]  D. Harville Maximum Likelihood Approaches to Variance Component Estimation and to Related Problems , 1977 .

[6]  Erik van Zwet,et al.  Heterogeneity in patient response in depression: The relevance of functional data analysis , 2008 .

[7]  Hojjat Adeli,et al.  Principal Component Analysis-Enhanced Cosine Radial Basis Function Neural Network for Robust Epilepsy and Seizure Detection , 2008, IEEE Transactions on Biomedical Engineering.

[8]  Giuseppe De Nicolao,et al.  Bayesian Population Modeling of Phase I Dose Escalation Studies: Gaussian Process Versus Parametric Approaches , 2011, IEEE Transactions on Biomedical Engineering.

[9]  R. Gomeni,et al.  Bayesian modelling and ROC analysis to predict placebo responders using clinical score measured in the initial weeks of treatment in depression trials. , 2007, British journal of clinical pharmacology.

[10]  R. Cattell The Scree Test For The Number Of Factors. , 1966, Multivariate behavioral research.

[11]  D. Reich,et al.  Principal components analysis corrects for stratification in genome-wide association studies , 2006, Nature Genetics.

[12]  Petre Stoica,et al.  Decentralized Control , 2018, The Control Systems Handbook.

[13]  R. Gomeni,et al.  Modelling placebo response in depression trials using a longitudinal model with informative dropout. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[14]  J. Edward Jackson,et al.  A User's Guide to Principal Components. , 1991 .

[15]  Michael Krams,et al.  Evaluation of structural models to describe the effect of placebo upon the time course of major depressive disorder , 2009, Journal of Pharmacokinetics and Pharmacodynamics.

[16]  M. Hamilton A RATING SCALE FOR DEPRESSION , 1960, Journal of neurology, neurosurgery, and psychiatry.

[17]  C. L. Mallows Some comments on C_p , 1973 .

[18]  Italo Poggesi,et al.  Model-based approaches to increase efficiency of drug development in schizophrenia: a can't miss opportunity , 2009, Expert opinion on drug discovery.

[19]  C. Mallows Some Comments on Cp , 2000, Technometrics.

[20]  Geert Molenberghs,et al.  Analyzing incomplete longitudinal clinical trial data. , 2004, Biostatistics.

[21]  Michael J. Black,et al.  Robust Principal Component Analysis for Computer Vision , 2001, ICCV.

[22]  J. E. Jackson A User's Guide to Principal Components , 1991 .

[23]  Meindert Danhof,et al.  Evaluation of treatment response in depression studies using a Bayesian parametric cure rate model. , 2008, Journal of psychiatric research.

[24]  D R Mould,et al.  Using Disease Progression Models as a Tool to Detect Drug Effect , 2007, Clinical pharmacology and therapeutics.

[25]  I. Jolliffe Principal Component Analysis , 2002 .

[26]  H. Abdi,et al.  Principal component analysis , 2010 .

[27]  Alkes L. Price,et al.  New approaches to population stratification in genome-wide association studies , 2010, Nature Reviews Genetics.

[28]  C. Mallows More comments on C p , 1995 .

[29]  J. L. Steimer,et al.  Variability in drug therapy : description, estimation, and control : a Sandoz workshop , 1985 .

[30]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[31]  J. Edward Jackson,et al.  A User's Guide to Principal Components: Jackson/User's Guide to Principal Components , 2004 .

[32]  Joshua M. Stuart,et al.  MICROARRAY EXPERIMENTS : APPLICATION TO SPORULATION TIME SERIES , 1999 .

[33]  Mark E. Sale,et al.  A Joint Model for Nonlinear Longitudinal Data with Informative Dropout , 2003, Journal of Pharmacokinetics and Pharmacodynamics.